Payment overview · 2025
General Payments
$2,791.35
129 reported records · 31 companies
Healthcare provider profile · identity verified
Rani Das, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · WEST LAKE HILLS, TX · NPI 1235165788
Verified facts
What the public records show
CMS Open Payments records show Rani Das, M.D. received $2,791.35 in general payments during 2025 across 129 reported records.
ABBVIE INC. accounted for 13.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Horizant, Nurtec Odt, Qulipta, Quviviq.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Qulipta by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported HORIZANT as an associated drug or biological on 2733 records involving 1696 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Horizant by this doctor in 2024.
IDORSIA PHARMACEUTICALS US INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QUVIVIQ as an associated drug or biological on 2281 records involving 1911 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Quviviq by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Nurtec Odt by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $368.62 | 13.2% | 21 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $238.13 | 8.5% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $217.10 | 7.8% | 12 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$204.57 | 7.3% | 10 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $195.82 | 7.0% | 9 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $170.38 | 6.1% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $161.10 | 5.8% | 4 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $147.01 | 5.3% | 11 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $124.14 | 4.5% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $108.12 | 3.9% | 6 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $105.08 | 3.8% | 6 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $83.99 | 3.0% | 4 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $70.09 | 2.5% | 3 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $68.58 | 2.5% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $66.74 | 2.4% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $61.42 | 2.2% | 3 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $49.76 | 1.8% | 3 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $46.99 | 1.7% | 1 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $43.28 | 1.6% | 2 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38.18 | 1.4% | 2 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $34.97 | 1.2% | 2 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $24.22 | 0.9% | 1 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $22.05 | 0.8% | 1 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $19.92 | 0.7% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $19.40 | 0.7% | 1 | 2025 |
| Vertical Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $18.82 | 0.7% | 1 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $18.72 | 0.7% | 1 | 2025 |
| OWP Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.37 | 0.7% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $17.89 | 0.6% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.00 | 0.5% | 1 | 2025 |
| Aucta Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.89 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,744.36 | 128 |
| Education | $46.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $368.62 | 21 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $238.13 | 10 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $217.10 | 12 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $208.81 | 15 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $198.94 | 11 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $161.10 | 4 | 2025 |
Source payment records
|
|||||
| RYLAZE Normalized: rylaze |
Drug | JAZZ PHARMACEUTICALS INC. | $158.85 | 7 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $147.01 | 11 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $145.24 | 2 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $117.22 | 1 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $87.02 | 5 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $87.02 | 5 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $83.99 | 4 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $77.07 | 5 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $70.09 | 3 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $68.58 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $66.74 | 3 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $61.42 | 3 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $53.16 | 3 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $49.76 | 3 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $44.95 | 3 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $43.28 | 2 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $38.18 | 2 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $34.97 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $28.01 | 1 | 2025 |
Source payment records
|
|||||
| ZEMBRACE SYMTOUCH Normalized: zembrace symtouch |
Drug | Tonix Medicines, Inc. | $24.22 | 1 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $22.05 | 1 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $19.82 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $19.40 | 1 | 2025 |
Source payment records
|
|||||
| Relexxii Normalized: relexxii |
Drug | Vertical Pharmaceuticals, LLC | $18.82 | 1 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $18.72 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $18.45 | 1 | 2025 |
Source payment records
|
|||||
| Subvenite Normalized: subvenite |
Drug | OWP Pharmaceuticals, Inc. | $18.37 | 1 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $17.89 | 1 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $17.15 | 1 | 2025 |
Source payment records
|
|||||
| HORIZANT Normalized: horizant |
Drug | Azurity Pharmaceuticals, Inc. | $14.00 | 1 | 2025 |
Source payment records
|
|||||
| Motpoly XR Normalized: motpoly xr |
Drug | Aucta Pharmaceuticals, Inc. | $13.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| HORIZANT horizant |
2025 | Horizant | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 52 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Quviviq quviviq |
2025 | Quviviq | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | HORIZANT open payments reported associated product |
CMS Open Payments — General Payments 2733 supporting records · 1696 recipient NPIs · example record 1242666828 |
Horizant · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| IDORSIA PHARMACEUTICALS US INC Exact reporting entity; no affiliate inference |
2025 | QUVIVIQ open payments reported associated product |
CMS Open Payments — General Payments 2281 supporting records · 1911 recipient NPIs · example record 1243392023 |
Quviviq · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
52 | 12 |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 692 | 144 |
| Donepezil Hcl | Donepezil Hcl | 671 | 166 |
| Tizanidine Hcl | Tizanidine Hcl | 447 | 103 |
| Memantine Hcl | Memantine Hcl | 308 | 65 |
| Trazodone Hcl | Trazodone Hcl | 226 | 42 |
| Lacosamide | Lacosamide | 174 | 28 |
| Levetiracetam | Levetiracetam | 147 | 31 |
| Lamotrigine | Lamotrigine | 143 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 142 | 31 |
| Zonisamide | Zonisamide | 138 | 25 |
| Belsomra | Suvorexant | 133 | 43 |
| Topiramate | Topiramate | 127 | 18 |
| Pregabalin | Pregabalin | 114 | 24 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 103 | 28 |
| Sertraline Hcl | Sertraline Hcl | 93 | 21 |
| Levetiracetam Er | Levetiracetam | 86 | 16 |
| Rivastigmine | Rivastigmine | 78 | 19 |
| Mirtazapine | Mirtazapine | 76 | 19 |
| Primidone | Primidone | 72 | 15 |
| Clonazepam | Clonazepam | 70 | 14 |
| Divalproex Sodium Er | Divalproex Sodium | 68 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 62 | suppressed |
| Armodafinil | Armodafinil | 56 | 16 |
| Nurtec Odt | Rimegepant Sulfate | 52 | 12 |
| Tramadol Hcl | Tramadol Hcl | 48 | suppressed |
| Briviact | Brivaracetam | 44 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 43 | 16 |
| Sumatriptan Succinate | Sumatriptan Succinate | 39 | suppressed |
| Bupropion Xl | Bupropion Hcl | 35 | 12 |
| Doxepin Hcl | Doxepin Hcl | 35 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 34 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 33 | 13 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 32 | suppressed |
| Phenobarbital | Phenobarbital | 31 | suppressed |
| Carbamazepine | Carbamazepine | 30 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | suppressed |
| Horizant | Gabapentin Enacarbil | 30 | suppressed |
| Modafinil | Modafinil | 30 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 29 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 29 | suppressed |
| Alprazolam | Alprazolam | 28 | 16 |
| Propranolol Hcl Er | Propranolol Hcl | 28 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 27 | suppressed |
| Qulipta | Atogepant | 26 | suppressed |
| Clobazam | Clobazam | 23 | suppressed |
| Eszopiclone | Eszopiclone | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 22 | suppressed |
| Prednisone | Prednisone | 21 | 18 |
| Emgality Pen | Galcanezumab-Gnlm | 19 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 17 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 17 | suppressed |
| Lamotrigine Er | Lamotrigine | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Carbamazepine Er | Carbamazepine | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Topamax | Topiramate | 14 | suppressed |
| Avonex Pen (4 Pack) | Interferon Beta-1a | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Quviviq | Daridorexant Hcl | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Topiramate Er | Topiramate | 13 | suppressed |
| Austedo | Deutetrabenazine | 12 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Adlarity | Donepezil Hcl | 11 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,791.35 · 129 records | ABBVIE INC. | AJOVY, AMYVID, AUSTEDO XR, Azstarys, BOTOX, BRIUMVI, CREXONT, Dyanavel XR, EPIDIOLEX, Gamunex-C, HORIZANT, KESIMPTA, KISUNLA, LEQEMBI, LUMRYZ, Motpoly XR, NUPLAZID, NURTEC ODT, Ocrevus Zunovo, QULIPTA, Qelbree, Quviviq, REXULTI, RYLAZE, Relexxii, Subvenite, Sunosi, Symbravo, TAVNEOS, TYSABRI, UBRELVY, ULTOMIRIS, VUMERITY, VYVGART HYTRULO, XYWAV, ZAVZPRET, ZEMBRACE SYMTOUCH | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Horizant play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error